# Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00967291** · PHASE2 · TERMINATED · sponsor: **IRCCS San Raffaele** · enrollment: 21 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** ifosfamide
- **DRUG:** mitomycin C

## Key facts

- **NCT ID:** NCT00967291
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** lack of activity and G3-4 toxicity at interim analysis
- **Last updated:** 2012-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967291, "Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00967291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*